These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
630 related articles for article (PubMed ID: 31541338)
1. Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer. Zhou C; Che G; Zheng X; Qiu J; Xie Z; Cong Y; Pei X; Zhang H; Sun H; Ma H J Cancer Res Clin Oncol; 2019 Nov; 145(11):2663-2674. PubMed ID: 31541338 [TBL] [Abstract][Full Text] [Related]
2. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma. Song Z; Yu X; Cheng G; Zhang Y J Transl Med; 2016 Jun; 14(1):188. PubMed ID: 27342566 [TBL] [Abstract][Full Text] [Related]
3. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma. Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662 [TBL] [Abstract][Full Text] [Related]
5. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868 [TBL] [Abstract][Full Text] [Related]
6. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments. Omori S; Kenmotsu H; Abe M; Watanabe R; Sugino T; Kobayashi H; Nakashima K; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Ohde Y; Endo M; Akiyama Y; Nakajima T; Takahashi T Int J Clin Oncol; 2018 Dec; 23(6):1052-1059. PubMed ID: 29948239 [TBL] [Abstract][Full Text] [Related]
7. MYC expression correlates with PD-L1 expression in non-small cell lung cancer. Kim EY; Kim A; Kim SK; Chang YS Lung Cancer; 2017 Aug; 110():63-67. PubMed ID: 28676221 [TBL] [Abstract][Full Text] [Related]
8. Programmed Cell Death Ligand 1 Expression in Non-Small-cell Lung Cancer Patients With Interstitial Lung Disease: A Matched Case-control Study. Fujimoto D; Sato Y; Morimoto T; Uehara K; Ito M; Otsuka K; Nagata K; Sakanoue I; Hamakawa H; Nakagawa A; Takahashi Y; Imai Y; Tomii K Clin Lung Cancer; 2018 Sep; 19(5):e667-e673. PubMed ID: 29844002 [TBL] [Abstract][Full Text] [Related]
9. Predictive value and molecular correlates of MYC immunohistochemistry and copy number gain in non-small cell lung carcinomas treated with immunotherapy. Naso J; Desai A; Smith CJ; Ashara YP; Yip S; Lo YC Lung Cancer; 2024 Sep; 195():107927. PubMed ID: 39173231 [TBL] [Abstract][Full Text] [Related]
10. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer. Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393 [TBL] [Abstract][Full Text] [Related]
11. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362 [TBL] [Abstract][Full Text] [Related]
12. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells. Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548 [No Abstract] [Full Text] [Related]
13. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma. Takada K; Okamoto T; Toyokawa G; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y Lung Cancer; 2017 Feb; 104():7-15. PubMed ID: 28213003 [TBL] [Abstract][Full Text] [Related]
14. Clinical significance of ≥ 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients. Li W; Song P; Guo L; Liu X; Guo C; Ying J; Gao S Thorac Cancer; 2019 Feb; 10(2):175-182. PubMed ID: 30536734 [TBL] [Abstract][Full Text] [Related]
15. Association Between Clinicopathological Features and Programmed Death Ligand 1 Expression in Non-small Cell Lung Cancer. Kato Y; Kashima J; Watanabe K; Yomota M; Zenke Y; Okuma Y; Hosomi Y; Gemma A; Seike M; Okamura T Anticancer Res; 2018 Feb; 38(2):1077-1083. PubMed ID: 29374744 [TBL] [Abstract][Full Text] [Related]
16. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas. Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153 [TBL] [Abstract][Full Text] [Related]
17. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma. Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750 [TBL] [Abstract][Full Text] [Related]
18. Clinicopathological significance of the expression of PD-L1 in non-small cell lung cancer. Montero MA; Aricak O; Kis L; Yoshikawa A; De Petris L; Grundberg O; Pham HHN; Roden AC; Fukuoka J; Attanoos R; Guijarro R; Alarcón F; Lindström K; Ortiz-Villalón C Ann Diagn Pathol; 2021 Apr; 51():151701. PubMed ID: 33485052 [TBL] [Abstract][Full Text] [Related]
19. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer. Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072 [TBL] [Abstract][Full Text] [Related]
20. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients. Takada K; Toyokawa G; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]